Yahoo · Nov 11, 2026
Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate
-Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates -Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate evaluated in 13 patients with relapsed or refractory multiple myeloma, including patients with extramedullary disease and prior CAR-T exposure -Encouraging preliminary clinical responses support option exercise, results planned for presentation at a major scientific conference BRISBANE, Calif., Nov. 11, 2026 (G

